Pharmaceutical impurities: A Review

Abhimanyu Thakur, Bishal Mishra, Partha Pratim Mahata

Abstract


A quality drug when marketed, has various factors associated with it one of the crucial factors being impurities identification at each stage of its development. Maintaing the quality, safety and efficacy of a drug indirectly protects the consumers’ right to health. A well accepted fact is that some impurities are unavoidable and will be present in trace amounts hence ICH comes into picture and through its guidelines and policies establishes the specification limits, evaluation and control of impurities. The regulatory bodies and drug development authorities look up to these guidelines for launching a quality drug into the market. Validation of analytical process for impurity identification is performed to establish the impurity profile of any drug substance. Hence the major focus of this review article is on characterisation of impurities, its sources, establishment of impurity profile and analytical approaches to establish its profile.


Keywords


Impurities, International Conference on Harmonization, Formulation, Profiling, Isolation.

Full Text:

PDF

References


Impurities in New Drug Substances, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Guideline Q3A (R2), 2006. Available at http://www.ich.org/LOB/media/ MEDIA422.pdf (Date of access: 12.11.2014)

Ahuja S, Alsante K M. Handbook of Isolation and Characterization of Impurities in Pharmaceuticals, Vol. 5, Separation Science and Technology, Academic press, 2003.

Roy J. Pharmaceutical Impurities–a mini review, AAPS PharmSciTech, 2002; 3(2): 1-8.

Federal Register (2000), “International Conferences on Harmonization”, Draft Revised Guidance on Impurities in New Drug Substances, Q3A(R), 45085-90.

International Conferences on Harmonization, Impurities—Guidelines for residual solvents. Q3C. Federal Register. 1997; 62 (247): 673-77.

International Conferences on Harmonization Specifications. Q6A: Test procedures and Acceptance Criteria for New drug substances and New drug products. Chemical Substances. 1999; 65 (146): 674-688.

International Conference on Harmonization guidelines Q3A (R) Impurities in New Drug Substances February 2002 (this guideline provides guidance for registration application on the content and qualification of impurities in new drug substances produced by the chemical synthesis).

Alsante KM, Hatajik TD, Lohr LL, and Sharp TR. Isolation and identification of process related impurities and degradation products from pharmaceutical drug candidates. Part 1. Amer. Pharm. Review. 2001; 4(1): 70-78.

ICH Harmonized Triplicate Guideline: Impurities in New Drug Substances Q3A (R2), ICH Steering Committee, Step 4 of ICH process, 25th Oct. 2006.

Josephs JL, Sanders M, Shipkova P. Detection and Characterization of Pharmaceutical Metabolites, Degradants and Impurities by the Application of MS / MS Software Algorithms; Technical Program. 25th Feb 2007.

Ahuja S. , Handbook of Modern Pharmaceutical analysis. Academic press. 2001; 298.

Poonam Kushwaha. The organic impurities in pharmaceuticals. Pharmainfo, 2008; 6(4).

Ahuja S. Isolation and characterization of pharmaceutical impurities evaluation. New York; Marcel Dekker. 2000.

Damle MC et al., Development and Validation of Stability Indicating HPTLC Method for Determination of Ofloxacin and Ketorolac Tromethamine in Combination, J. Adv. Sci. Res. 2011; 2 (3): 77-82.

Connor KA, Amidon GL, Stella VJ. Chemical Stability of Pharmaceuticals – A handbook for pharmacists. New York: John Wiley & Sons. 1986.

Parimoo P et al. ‘A Text Book of Pharmaceutical Analysis’, CBS publishers and distributors, New Delhi, 1998; 14.

Koji U. Atsuya H, kazuichi U, Masayuki G. Matrix media selection for the determination of residual solvents in pharmaceutical by static head space chromatography, J. Chrom. A. 2004; 1057: 203 – 210.

Anil M. Dwivedi. Residual solvent analysis in pharmaceuticals. Int. J. Pharma. Excip, 2003; April - june: 33 – 37.

Tagg J. et al., Metabolic studies of tolbutamide in the rat., Biochem. Pharmacol. 16 (1) 143–153 (1967).

Ahuja S, (1997) Chiral Separations by Chromatography, Oxford University Press, NY, p-365.

Ahuja S and Scypinski S (2001) Handbook of Modern Pharmaceutical Analysis, Academic Press, NY, p. 298

Ahuja S (1992) Trace and Ultra trace Analysis by HPLC, Willey, New York, p. 84

ICH Harmonised Tripartite Guideline Validation of Analytical Procedures: text and methodology Q2 (R1).

Roy J, Islam M, Khan AH, Das SC, Akhteruzzaman M, Deb AK, Alam AH M. Diclofenac sodium injection sterilized by autoclave and the occurrence of cyclic reaction producing a small amount of impurity. J. Pharm. Sci. 2001; (90): 541- 544.

Hogerzeil HV, Battersby A, Srdanovic V, and Stjernstrom NE. Stability of essential drugs during shipment to the tropics. BMJ. 1992; 304: 210-214.




DOI: http://dx.doi.org/10.7439/ijpc.v5i7.2140

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Refbacks

  • There are currently no refbacks.


Copyright (c) 2015 International Journal of Pharmaceutical Chemistry

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.